Genetic Markers for Liver Cancer Found in Blood and Saliva
Researchers examined markers of liver cancer and found that the disease can be recognized by RNA fragments in saliva and blood.
Category: Unknown Origin & Other Cancer Types
Unknown Origin & Other Cancer Types
Latest
Unknown Origin & Other Cancer Types
Latest
Viruses May Impact Health Long After infection
Cells undergo long-term changes after viral infection, pointing to why hepatitis C patients are susceptible to liver cancer.
Unknown Origin & Other Cancer Types
Latest
Birmingham University, Nonacus Partner to Develop Urine Test for Bladder Cancer
The urine test, which is expected to be available by mid-2022, will use highly sensitive liquid biopsy technology developed by Nonacus and a panel of biomarkers validated by Birmingham University researchers to diagnose bladder cancer.
Qlucore Awarded Grant to Aid Clinical Diagnostics of Cancer
The grant will allow Qlucore to expand Qlucore Diagnostics software with a focus on RNA-profiling of glioma and acute leukemia.
Read More
TissueCypher Accurately Predicts Progression to Esophageal Cancer in Patients with Barrett’s Esophagus
Cernostics’ TissueCypher Barrett’s Esophagus Assay was able to identify non-dysplastic Barrett’s esophagus patients at high risk for progression to cancer who are missed by current standard of care.
Read More
FDA Approves New FoundationOne Liquid CDx Companion Diagnostic Indications for 3 Cancer Therapies
FDA approved FoundationOne Liquid CDx for three new companion diagnostic indications: Piqray in advanced or metastatic breast cancer; Rubraca in advanced ovarian cancer; and Alecensa in a certain type of metastatic non-small cell lung cancer.
Read More
Breakthrough Blood Test Developed for Brain Tumors
Research shows a noninvasive ddPCR test can help physicians diagnose and monitor the clinical progress of patients with gliomas.
Read More
Tumor Gene Test Could Help Predict Ovarian Cancer Prognosis
A tumor gene test could help identify ovarian cancer patients with predicted poor survival and inform new therapeutical approaches, study results show.
Read More
NuView Life Sciences Secures $90M for NV-VPAC1 Cancer Portfolio
NuView Life Sciences will use the funds to complete a 600-patient in vitro double-blind clinical trial for the NV-VPAC1 cancer portfolio.
Read More
Merus, Caris Life Sciences Collaborate to Detect NRG1 Fusions in Cancer Patients
Caris will provide DNA and RNA molecular testing to support patient identification and enrollment for Merus’ Zenocutuzumab Phase 1/2 eNRGy trial.
Read MoreDecipher Identifies Bladder Cancer Patients Most Likely to Benefit from Neoadjuvant Immunotherapy
Patients with muscle-invasive bladder cancer who had the molecular subtype basal claudin low received the greatest benefit from Keytruda immunotherapy.
Read More
Blood Test May Help Doctors Catch Pancreatic Cancer Early
Penn study shows liquid biopsy may be viable option for both diagnosis and disease staging of pancreatic cancer.
Read More
Multicancer Blood Test, Combined with Imaging, Shows Promise as Screen for Cancer
The blood test followed by PET-CT imaging was 99.6% specific for cancer.
Read More
Interventional Study to Evaluate Multicancer Early Detection Test
The Pathfinder study will enroll 6,200 participants to evaluate Grail’s investigational multicancer early detection test in clinical practice.
Read More
Myriad Submits Supplemental PMA for myChoice Companion Diagnostic
Myriad’s myChoice companion diagnostic helps identify women with ovarian cancer who are candidates for maintenance therapy using olaparib with bevacizumab.
Read More
Renal Cell Carcinoma Liquid Biopsy Trial Underway
The AUR87A trial will involve 16 hospitals across Europe and the United States, making it the largest-ever prospective multicenter study of a diagnostic for the detection of recurrence after surgery in clear cell renal cell carcinoma.
Read More
Study Offers Promise for Multicancer Detection from a Single Blood Draw
Bluestar Genomics’ technology can noninvasively detect cancers and help identify the underlying biology of the disease using epigenetic markers.
Read MoremiR Scientific Introduces Sentinel Disease Management Platform
The Sentinel disease management platform incorporates a number of noninvasive liquid biopsy urine tests that can help accurately detect, score, and monitor urological cancers.
Read More